Toggle light / dark theme

If the coordination of DNA and RNA epigenetics gets thrown off, you may end up with too much or too little of a protein, Fuk suggested. “Now, a key protein will be expressed at a too high level,” he said.” This could be detrimental for a cell and contribute to tumorigenesis,” or the formation of tumors.

There are already approved therapies that inhibit the methylation of DNA, and there’s an early-phase clinical trial testing RNA methylation inhibition as a cancer treatment. Fuks and his team are testing the potential of combining these existing therapies to improve patients’ outcomes. Preliminary data from their laboratory studies hint this strategy could be useful for patients with leukemia.

Go to https://historicmail.com/DROID and check out with code DROID to get 10% off on their Christmas Sale on your gifts and help support the channel. Thanks to Historic Mail for sponsoring this video!
Machines so tiny they would be far smaller than a human blood cell, this is the promise of nanotechnology, and they already exist but how are they even made and will they be scarier than A.I. Experts say that we are just at the beginning of the nanobot revolution and what they promise could little short of miraculous. In this video we look at how we got here and what the current state of the art is.

To give one off tips and donations please use the following :
https://www.buymeacoffee.com/curiousdroid.

Patreon : https://www.patreon.com/curiousdroid — For longer term channel support.

Paypal.me : https://paypal.me/curiousdroid — For 1 off direct tips and thank you payments.

Researchers, led by the University of Melbourne’s Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in collaboration with Pfizer, have discovered new insights into possible future treatments for breast cancer.

A new dual-target drug that has been shown to supercharge cancer-fighting immune cells in mice may support a new treatment approach for patients, potentially paving the way for improved outcomes in breast cancer care.

Breast cancer is the fifth most common cause of cancer death in Australia, with more than 20,000 Australians diagnosed per year. Over 1,000 of those diagnosed are young Australian women under 40. There is an urgent need to discover more effective treatments for breast cancer.

A new blood test developed by researchers at Oregon Health & Science University (OHSU) shows promise for the early detection of pancreatic cancer, a disease notorious for its high mortality rates due to late diagnosis.

The test, named PAC-MANN, which stands for “protease activity-based assay using a magnetic nanosensor,” could provide a critical tool for doctors.

It can potentially lead to improved survival rates for patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), the most prevalent and aggressive form of pancreatic cancer.

Aging is a natural process, but for centuries, humans have been searching for ways to slow it down or even reverse it. Recent advancements in stem cell research and regenerative medicine have given scientists unprecedented insights into aging and potential interventions. With breakthroughs in cellular therapy, gene editing, and tissue engineering, we are closer than ever to finding ways to rejuvenate the human body. But how close are we to reversing aging, and what challenges remain?

Stem cells are the body’s raw materials from which all other specialized cells are generated. They have the unique ability to divide and create identical copies of themselves (self-renewal) or differentiate into specialized cell types. However, as we age, our stem cells decline in both number and efficiency, contributing to tissue degeneration, slower healing, and an increased risk of age-related diseases.

Researchers have been investigating how stem cells can be manipulated to repair damaged tissues, regenerate organs, and potentially reverse signs of aging. By harnessing stem cells, scientists aim to restore youthful function in various tissues and organs, offering promising anti-aging therapies.

Summary: New research provides direct evidence that the gut microbiome communicates with the brain through the vagus nerve. Using germ-free mice, scientists observed significantly reduced vagal nerve activity, which returned to normal after introducing gut bacteria.

When antibiotics were used to eliminate bacteria in normal mice, vagal activity dropped but was restored when microbiome-derived intestinal fluids were reintroduced. Specific metabolites, including short-chain fatty acids and bile acids, were identified as key activators of vagal neurons.

These signals extended to the brainstem, confirming a clear gut-to-brain pathway. The findings advance understanding of the gut-brain axis and may lead to new treatments for neurological and gastrointestinal disorders.

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of arsenic trioxide (Oral-ATO; ARSENOL) for the treatment of acute promyelocytic leukemia (APL), a blood cancer that once had a high fatality rate.

The invention and use of oral-ATO is of historic importance for medicine in Hong Kong. It is the first-ever prescription medication wholly invented and manufactured in Hong Kong, and also the first to obtain U.S., European and Japanese patents.

After more than two decades of dedicated work, the HKU research team successfully translated this Hong Kong invention into by incorporating oral-ATO into the treatment plan of APL patients. Extensive clinical studies of oral-ATO have demonstrated its high efficacy and safety in curing APL patients, with an overall survival (OS) rate exceeding 97%, along with a significant reduction in side-effects and treatment burden.

Researchers at Washington University School of Medicine in St. Louis have conducted a longitudinal study on an individual carrying the presenilin 2 (PSEN2) p. Asn141Ile mutation, a genetic variant known to cause dominantly inherited Alzheimer’s disease (DIAD). The high risk individual, despite being 18 years past the expected age of clinical onset, has remained cognitively intact. Researchers investigated genetic, neuroimaging, and biomarker data to understand potential protective mechanisms.

Unlike typical DIAD progression, in this case was confined to the occipital lobe without spreading, suggesting a possible explanation for the lack of cognitive decline.

DIAD results from highly penetrant mutations in (APP), presenilin 1 (PSEN1), or PSEN2, which lead to abnormal amyloid-β processing and early-onset Alzheimer’s disease. The Dominantly Inherited Alzheimer Network (DIAN) was established to track DIAD mutation carriers and assess clinical, cognitive, and biomarker changes over time.

They say that change takes time. Well, that’s not the case for RNA. The small biological molecule acts like a switchboard operator, capable of changing its shape every few milliseconds so it can manipulate biological functions in the body. It has big jobs to carry out, after all, like copying genetic information into every living cell and activating the immune response.

A new multidisciplinary study from biophysicists and virologists at the UNC School of Medicine challenges this idea of shape-shifting RNA. Helen Lazear, Ph.D., associate professor of microbiology and immunology, and Qi Zhang, Ph.D., professor of biochemistry and biophysics, have discovered that a type of RNA in Zika virus, a mosquito-borne virus, can essentially freeze itself in time in an effort to make more copies of itself and further its spread in the body.

Their findings have not only sent ripples through the field of virology, but it has also given researchers new ammunition in the fight against RNA viruses. Their study, which was published in Nature Chemical Biology, paves the way for new therapies that can “unfreeze” these RNA structures to combat other mosquito-borne RNA viruses.